Aggressive surgical effort and improved survival in advanced-stage ovarian cancer
- PMID: 16394043
- DOI: 10.1097/01.AOG.0000192407.04428.bb
Aggressive surgical effort and improved survival in advanced-stage ovarian cancer
Abstract
Objective: Residual disease after initial surgery for ovarian cancer is the strongest prognostic factor for survival. However, the extent of surgical resection required to achieve optimal cytoreduction is controversial. Our goal was to estimate the effect of aggressive surgical resection on ovarian cancer patient survival.
Methods: A retrospective cohort study of consecutive patients with International Federation of Gynecology and Obstetrics stage IIIC ovarian cancer undergoing primary surgery was conducted between January 1, 1994, and December 31, 1998. The main outcome measures were residual disease after cytoreduction, frequency of radical surgical resection, and 5-year disease-specific survival.
Results: The study comprised 194 patients, including 144 with carcinomatosis. The mean patient age and follow-up time were 64.4 and 3.5 years, respectively. After surgery, 131 (67.5%) of the 194 patients had less than 1 cm of residual disease (definition of optimal cytoreduction). Considering all patients, residual disease was the only independent predictor of survival; the need to perform radical procedures to achieve optimal cytoreduction was not associated with a decrease in survival. For the subgroup of patients with carcinomatosis, residual disease and the performance of radical surgical procedures were the only independent predictors. Disease-specific survival was markedly improved for patients with carcinomatosis operated on by surgeons who most frequently used radical procedures compared with those least likely to use radical procedures (44% versus 17%, P < .001).
Conclusion: Overall, residual disease was the only independent predictor of survival. Minimizing residual disease through aggressive surgical resection was beneficial, especially in patients with carcinomatosis.
Level of evidence: II-2.
Similar articles
-
Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.Gynecol Oncol. 1999 Mar;72(3):278-87. doi: 10.1006/gyno.1998.5145. Gynecol Oncol. 1999. PMID: 10053096
-
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.Gynecol Oncol. 2006 Dec;103(3):1083-90. doi: 10.1016/j.ygyno.2006.06.028. Epub 2006 Aug 4. Gynecol Oncol. 2006. PMID: 16890277
-
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecol Oncol. 2006 Nov;103(2):559-64. doi: 10.1016/j.ygyno.2006.03.051. Epub 2006 May 22. Gynecol Oncol. 2006. PMID: 16714056
-
Epithelial ovarian carcinoma: principles of primary surgery.Gynecol Oncol. 1994 Dec;55(3 Pt 2):S91-6. doi: 10.1006/gyno.1994.1346. Gynecol Oncol. 1994. PMID: 7835815 Review.
-
[Surgery in ovarian carcinoma].Gan To Kagaku Ryoho. 1995 Aug;22(9):1176-81. Gan To Kagaku Ryoho. 1995. PMID: 7661569 Review. Japanese.
Cited by
-
Prognostic impact of microscopic residual disease after neoadjuvant chemotherapy in patients undergoing interval debulking surgery for advanced ovarian cancer.Arch Gynecol Obstet. 2024 Oct 13. doi: 10.1007/s00404-024-07775-w. Online ahead of print. Arch Gynecol Obstet. 2024. PMID: 39397086
-
The Impact of Upper Abdominal Surgery Regarding the Outcome of Patients with Advanced Ovarian Cancer.Geburtshilfe Frauenheilkd. 2024 Jul 4;84(9):866-875. doi: 10.1055/a-2331-0900. eCollection 2024 Sep. Geburtshilfe Frauenheilkd. 2024. PMID: 39229631 Free PMC article.
-
Radiomics combined with clinical and MRI features may provide preoperative evaluation of suboptimal debulking surgery for serous ovarian carcinoma.Abdom Radiol (NY). 2024 Jul 14. doi: 10.1007/s00261-024-04343-3. Online ahead of print. Abdom Radiol (NY). 2024. PMID: 39003651
-
The survival benefit associated with complete macroscopic resection in epithelial ovarian cancer is histotype specific.JNCI Cancer Spectr. 2024 Jul 1;8(4):pkae049. doi: 10.1093/jncics/pkae049. JNCI Cancer Spectr. 2024. PMID: 38902938 Free PMC article.
-
Clinical value of serum tumor markers in assessing the efficacy of neoadjuvant chemotherapy in advanced ovarian cancer: single-center prospective clinical study.Front Oncol. 2024 May 28;14:1399502. doi: 10.3389/fonc.2024.1399502. eCollection 2024. Front Oncol. 2024. PMID: 38863620 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials

